Chemotherapy advances in small cell lung cancer

G. Rosti, O. Carminati, M. Monti, S. Tamberi, M. Marangolo

Research output: Contribution to journalArticle

Abstract

Small cell lung cancer accounts for 13-15% of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except probably to changing in smoking habits in the last two decades. In the early 1980s, it became clear that SCLC was an extremely sensitive tumour to radiation as it was to chemotherapeutic agents. With cisplatinum etoposide combinations or cyclophosphamide, anthracycline and vincristine/etyoposide regimens responses were observed in 50-70%, with 20-30% complete remissions in extensive disease. For limited-stage patients chemotherapy associated with thoracic radiation was able to produce a cure rate of 10-20%.The addition of prophylactic brain irradiation to limited stage cases has reduced mortality by a factor of nearly 5%. But despite these early good results no breakthrough came later on, and in the last decade or so, we are still facing this plateau. New agents have recently been included in the therapeutic armamentarium, such as gemcitabine, irinotecan, paclitaxel and more recently pemetrexed. This fact has allowed many patients to receive a relatively active second line therapy, but the overall survival remains unchanged. Targeted therapies are undergoing some evaluations, but the data are too premature and, so far, quite discouraging. At the present time there is an urgent need to improve clinical research in this somehow forgotten disease.

Original languageEnglish
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 5
DOIs
Publication statusPublished - May 2006

Fingerprint

Small Cell Lung Carcinoma
irinotecan
gemcitabine
Drug Therapy
Pemetrexed
Radiation
Anthracyclines
Vincristine
Etoposide
Paclitaxel
Cyclophosphamide
Habits
Lung Neoplasms
Thorax
Therapeutics
Smoking
Survival
Mortality
Brain
Research

Keywords

  • Chemotherapy
  • Small cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rosti, G., Carminati, O., Monti, M., Tamberi, S., & Marangolo, M. (2006). Chemotherapy advances in small cell lung cancer. Annals of Oncology, 17(SUPPL. 5). https://doi.org/10.1093/annonc/mdj961

Chemotherapy advances in small cell lung cancer. / Rosti, G.; Carminati, O.; Monti, M.; Tamberi, S.; Marangolo, M.

In: Annals of Oncology, Vol. 17, No. SUPPL. 5, 05.2006.

Research output: Contribution to journalArticle

Rosti, G, Carminati, O, Monti, M, Tamberi, S & Marangolo, M 2006, 'Chemotherapy advances in small cell lung cancer', Annals of Oncology, vol. 17, no. SUPPL. 5. https://doi.org/10.1093/annonc/mdj961
Rosti, G. ; Carminati, O. ; Monti, M. ; Tamberi, S. ; Marangolo, M. / Chemotherapy advances in small cell lung cancer. In: Annals of Oncology. 2006 ; Vol. 17, No. SUPPL. 5.
@article{7da2001d37f5466a9bbf049ed3c9164d,
title = "Chemotherapy advances in small cell lung cancer",
abstract = "Small cell lung cancer accounts for 13-15{\%} of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except probably to changing in smoking habits in the last two decades. In the early 1980s, it became clear that SCLC was an extremely sensitive tumour to radiation as it was to chemotherapeutic agents. With cisplatinum etoposide combinations or cyclophosphamide, anthracycline and vincristine/etyoposide regimens responses were observed in 50-70{\%}, with 20-30{\%} complete remissions in extensive disease. For limited-stage patients chemotherapy associated with thoracic radiation was able to produce a cure rate of 10-20{\%}.The addition of prophylactic brain irradiation to limited stage cases has reduced mortality by a factor of nearly 5{\%}. But despite these early good results no breakthrough came later on, and in the last decade or so, we are still facing this plateau. New agents have recently been included in the therapeutic armamentarium, such as gemcitabine, irinotecan, paclitaxel and more recently pemetrexed. This fact has allowed many patients to receive a relatively active second line therapy, but the overall survival remains unchanged. Targeted therapies are undergoing some evaluations, but the data are too premature and, so far, quite discouraging. At the present time there is an urgent need to improve clinical research in this somehow forgotten disease.",
keywords = "Chemotherapy, Small cell lung cancer, Targeted therapy",
author = "G. Rosti and O. Carminati and M. Monti and S. Tamberi and M. Marangolo",
year = "2006",
month = "5",
doi = "10.1093/annonc/mdj961",
language = "English",
volume = "17",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Chemotherapy advances in small cell lung cancer

AU - Rosti, G.

AU - Carminati, O.

AU - Monti, M.

AU - Tamberi, S.

AU - Marangolo, M.

PY - 2006/5

Y1 - 2006/5

N2 - Small cell lung cancer accounts for 13-15% of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except probably to changing in smoking habits in the last two decades. In the early 1980s, it became clear that SCLC was an extremely sensitive tumour to radiation as it was to chemotherapeutic agents. With cisplatinum etoposide combinations or cyclophosphamide, anthracycline and vincristine/etyoposide regimens responses were observed in 50-70%, with 20-30% complete remissions in extensive disease. For limited-stage patients chemotherapy associated with thoracic radiation was able to produce a cure rate of 10-20%.The addition of prophylactic brain irradiation to limited stage cases has reduced mortality by a factor of nearly 5%. But despite these early good results no breakthrough came later on, and in the last decade or so, we are still facing this plateau. New agents have recently been included in the therapeutic armamentarium, such as gemcitabine, irinotecan, paclitaxel and more recently pemetrexed. This fact has allowed many patients to receive a relatively active second line therapy, but the overall survival remains unchanged. Targeted therapies are undergoing some evaluations, but the data are too premature and, so far, quite discouraging. At the present time there is an urgent need to improve clinical research in this somehow forgotten disease.

AB - Small cell lung cancer accounts for 13-15% of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except probably to changing in smoking habits in the last two decades. In the early 1980s, it became clear that SCLC was an extremely sensitive tumour to radiation as it was to chemotherapeutic agents. With cisplatinum etoposide combinations or cyclophosphamide, anthracycline and vincristine/etyoposide regimens responses were observed in 50-70%, with 20-30% complete remissions in extensive disease. For limited-stage patients chemotherapy associated with thoracic radiation was able to produce a cure rate of 10-20%.The addition of prophylactic brain irradiation to limited stage cases has reduced mortality by a factor of nearly 5%. But despite these early good results no breakthrough came later on, and in the last decade or so, we are still facing this plateau. New agents have recently been included in the therapeutic armamentarium, such as gemcitabine, irinotecan, paclitaxel and more recently pemetrexed. This fact has allowed many patients to receive a relatively active second line therapy, but the overall survival remains unchanged. Targeted therapies are undergoing some evaluations, but the data are too premature and, so far, quite discouraging. At the present time there is an urgent need to improve clinical research in this somehow forgotten disease.

KW - Chemotherapy

KW - Small cell lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=33745584397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745584397&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj961

DO - 10.1093/annonc/mdj961

M3 - Article

C2 - 16807475

AN - SCOPUS:33745584397

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -